Loading clinical trials...

Blended Care for the Discontinuation of Benzodiazepine Use | Clinical Trials | Clareo Health

COMPLETEDNA

Blended Care for the Discontinuation of Benzodiazepine Use

The Effectiveness of a Blended Care Program for the Discontinuation of Benzodiazepines Use for Sleeping Problems in Primary Care: a Clustered Randomized Trial.

NCT03937180•Kristien Coteur

View on ClinicalTrials.gov

Summary

This study aims to compare two strategies performed by GPs to help patients taking benzodiazepines on a daily basis for at least six months to discontinue their use. The first strategy consists of the usual or standard support provided by the GP, which often starts with a discontinuation advice or letter, the second is blended support where face-to-face consultations with the GP are alternated with web-based self-learning by the patient.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients aged 18 and older capable of giving informed consent,
•Having his/her Global Medical File managed by one of the participating general practitioners
•Receiving prescriptions of (z-)BZDs from participating GP for use on a daily basis
•Reporting daily intake (≥ 80% of days) of (z-)BZDs in the last 6 months for a primary indication of sleeping problems

Exclusion Criteria

•Presence of any severe psychiatric and neurologic condition that in the judgment of the treating GP implies a contraindication for (z-)BZD withdrawal
•Presence of terminal illness
•Any cases where stopping of (z-)BZDs might be harmful
•Unwillingness or inability to provide informed consent
•Not having e-literacy (being familiar with email and internet use)
•Patients with a substance use disorder (other than (z-)BZD) will also be excluded from the study because in these cases there is often a sub-therapeutic (z-)BZD dependence and/or comorbid psychological/psychiatric comorbid conditions requiring specialist care.

Locations (110)

Leysen Bert

Broechem, Antwerpen, Belgium

Asselman Valerie

Hoboken, Antwerpen, Belgium

Van Tongelen Sofie

Mechelen, Antwerpen, Belgium

Thomas Pol

Jette, Brussels Capital, Belgium

Maquet Elisabeth

Saint-Gilles, Brussels Capital, Belgium

Fauquert Benjamin

Schaarbeek, Brussels Capital, Belgium

Uhry Franck

Uccle, Brussels Capital, Belgium

Vansintejan Johan

Vilvoorde, Brussels Capital, Belgium

Bedoret Virginie

Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Brussels Capital, Belgium

Catinus Pierric

Châtelineau, Henegouwen, Belgium

Key Dates

Start Date

June 24, 2019

Primary Completion Date

July 30, 2021

Completion Date

August 2, 2021

Last Updated

July 15, 2022

Enrollment

924

ACTUAL participants

Conditions

Benzodiazepine DependenceBenzodiazepine DependentBenzodiazepine Withdrawal

Interventions

Blended care

BEHAVIORAL

Usual care

BEHAVIORAL

Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence

NCT05935553

Benzodiazepine Dependence

View study

RECRUITINGNA

Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users

NCT06446349

Benzodiazepine Withdrawal

View study

RECRUITINGNA

Can Connected Devices Increase the Success Rate of Benzodiazepine Withdrawals in the Elderly?

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 15, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.